KEYNOTE B61 Extended Follow Up of Lenvatinib plus Pembrolizumab in nccRCC 1L

Opinion
Video

An expert discusses key data points from the KEYNOTE B61 extended follow up of Lenvatinib plus pembrolizumab in first line setting in non-clear cell renal cell carcinoma.

Recent Videos
Mazyar Shadman, MD, MPH, an expert on CLL
Mazyar Shadman, MD, MPH, an expert on CLL
Mazyar Shadman, MD, MPH, an expert on CLL
Mazyar Shadman, MD, MPH, an expert on CLL
2 KOLs are featured in this program.
2 KOLs are featured in this program.
Martin H. Voss, MD, an expert on kidney cancer
2 KOLs are featured in this program.
2 KOLs are featured in this program.
Martin H. Voss, MD, an expert on kidney cancer